Citations

Showing 10 of 107868 citations.

Modulation of miRNA Signature in Human Adipose Tissue After 3 Months of ω-3PUFA Supplementation
Hernandez, James , Lee, Matthew, Cochran, Mary, Li, Ting, Wang, Panwen , Coletta, Dawn K. , Rau, Cassandra M., Dinu, Valentin , Filippis, Eleanna De , Dinu, Valentin , De Filippis, Eleanna , Coletta, Dawn K

Mayo Clinic

Cells | March 25, 2026 | Volume: 15 | Issue: 7 | Pages: 577

10.3390/cells15070577 | PMID 41972668 Get It

Obesity is a persistent public health issue, often resulting in metabolic complications such as insulin resistance (IR). The secretion of pro-inflammatory cytokines from adipose tissue (AT) is increased during obesity, contributing to the impairment of systemic insulin sensitivity. While interventions in animal models have shown that reducing inflammation restores insulin sensitivity, human studies reducing systemic inflammation have produced inconsistent results. We recently demonstrated that three months of high-dose (4 g/daily) ω-3PUFA (fish oil, FO) supplementation improved insulin sensitivity, and decreased systemic and AT inflammation in individuals with obesity (BMI ≥ 30 kg/m2). Given recent studies highlighting the involvement of microRNA (miRNA) in inflammatory cytokine production, we investigated the effect of ω-3PUFA supplementation on AT miRNA expression in this cohort. AT biopsies were collected before and after ω-3PUFA supplementation. miRNA was processed on the Affymetrix miRNA 4.0 GeneChip and analyzed using existing inflammatory gene sets sourced from MSigDB. Unbiased, differentially expressed miRNA analysis identified miR-4498 and miR-5689 as significantly increased after three months of ω-3PUFA supplementation. Real-time PCR confirmed bioinformatic analysis findings. Our study reports the modulation of miRNA in AT, reductions in systemic and AT markers of inflammation, and the improvement of IR post ω-3PUFA supplementation. Further research is needed to elucidate the link between miR-4498, miR-5689, and whole-body insulin sensitivity.
Ketamine Use in Self-Described Therapeutic Contexts: A Thematic Analysis of Reddit Posts
Kendrick, J. Richard, Ahmad, Ghonwa, Wood, Audrey, Stumo, Samuel , Sehgal, Aarav, Matthews, Douglas B. , Sharma, Pravesh , Sharma, Pravesh , Matthews, Douglas B , Kendrick, Jared

Mayo Clinic

Behavioral Sciences | March 25, 2026 | Volume: 16 | Issue: 4 | Pages: 480

10.3390/bs16040480 | PMID 42073843 Get It

The use of ketamine for the management of neuropsychiatric conditions outside clinical settings has rapidly expanded, creating a critical need to understand diverse individual experiences. We conducted a qualitative content analysis of posts from the r/TherapeuticKetamine subreddit. From 3302 threads, the 500 highest-engagement threads (12,852 comments) were analyzed by independent coders across six domains: perceived positive effects, adverse effects, reasons for use, route of administration, polydrug use, and dose amounts. Mood-related concerns were the primary reason for use (53%). Users reported positive effects, most often improvements in emotional well-being (65%). Adverse effects were predominantly psychological or mood-related (56%). A total of 70% of reported doses exceeded 149 mg, suggesting a trend toward higher dose use. Intravenous administration (40%) and sublingual troches (23%) were the most frequently reported routes. Concurrent use of prescribed psychotropics, cannabis, and psychedelics was also reported. This analysis identified substantial heterogeneity in individual-reported experiences. Frequent high-dose use, dose escalation, and polydrug exposure underscores the importance of clinical monitoring and attention to addiction potential and drug–drug interactions. The findings should be interpreted with caution, as follow-up and clinical verification were not possible; however, the data provide an unfiltered view of individual experiences in relation to ketamine use outside the clinical setting.
Evolution and Transformation of Hypertrophic Cardiomyopathy From a High Risk to a Treatable Low Mortality Disease With Contemporary Clinical Research Strategies
Maron, Barry J. , Ommen, Steven R., Ra, Nishimura, McKenna, William J. , Rakowski, H., Olivotto, I, Braunwald, Eugene, Maron, Martin S., Nishimura, Rick A. , McKenna, William J. , Olivotto, Iacopo , Ommen, Steve R , Nishimura, Rick A , Rakowski, Harry , Sherrid, Mark , Olivotto, Iacopo , Maron, Martin S , Maron, Barry J. , Ommen, Steve R. , Sherrid, Mark V. , Braunwald, Eugene , Maron, Martin S.

Mayo Clinic

Journal of the American Heart Association | March 25, 2026 | Volume: 15 | Issue: 12 | Pages: No page available

10.1161/jaha.125.047462 | PMID 41878858 Get It

Once considered rare and essentially untreatable with a grim prognosis and reduced life expectancy, hypertrophic cardiomyopathy (HCM) has evolved substantially over 6 decades. Ultimately, HCM has become a contemporary global disease with pharmacologic and interventional options offering effective personalized treatment for all adverse disease pathways. Striking reduction in HCM‐related mortality to ≤0.5%/year in optimally treated cohorts is now comparable to that expected in the US general population, lower than most other disease risks to living, and 10‐fold less than the earliest estimates. The few deaths directly related to HCM are now largely attributable to advanced (end‐stage) heart failure in patients with nonobstructive HCM. Determinants of this transformation to a lower risk disease are evident in hallmark clinical inflection points and breakthroughs, including dedicated HCM programs assembling large clinical databases in which focused (and unfunded) physician‐investigators have derived data directly from patients in clinical practice. Evidence‐based observational studies report emergence of contemporary treatment strategies enhancing survival: implantable defibrillators prevent arrhythmic sudden death globally with 95% sensitive patient selection using an American Heart Association/American College Cardiology risk stratification algorithm; low‐risk, high‐benefit surgical myectomy reverses outflow obstruction and heart failure in >90% with a long‐term survival benefit; and aggressive anticoagulation has reduced embolic strokes. Recent novel pharmacologic alternatives (cardiac myosin inhibitors) are proving effective in relieving obstruction/symptom burden and changing disease management. These principles and time‐tested patient‐centered research strategies uniquely tailored to the heterogeneous HCM clinical spectrum are pivotal in providing practice insights, offering a vulnerable population more optimistic prognosis including opportunity to achieve normal longevity not available to prior generations of patients.
Sociodemographic and Clinical Predictors of Mortality in Adults With Congenital Heart Disease
O'Sullivan, D, Samimi, Sahar , Anjewierdan, Scott , Wi, Chung‐Il, Lopez, Keila N. , Egbe, Alexander, Watson, Dave , Jain, C. Charlie, Juhn, Young J. , Miranda, William R. , Connolly, Heidi M., Madhavan, Malini, Burchill, Luke J., Wi, Chung‐Il , O’Sullivan, Donnchadh , O'Sullivan, Donnchadh , Wi, Chung-Ii , Egbe, Alexander C , Charles Jain, C , Connolly, Heidi M , Madhavan, Malini , Burchill, Luke J , Lopez, Keila N , Anjewierden, Scott , Jain, C. Charles , Connolly, Heidi M. , Madhavan, Malini , Burchill, Luke J.

Mayo Clinic

Journal of the American Heart Association | March 25, 2026 | Volume: 15 | Issue: 7 | Pages: No page available

10.1161/jaha.125.045411 | PMID 41878868 Get It

Background Mortality in adults with congenital heart disease (CHD) is strongly driven by disease complexity. Social determinants of health (SDOH) influence adult CHD (ACHD) health outcomes but their impact on mortality is unclear. This study examined the influence of clinical factors and SDOH on all‐cause mortality in patients with ACHD. Methods Single‐center retrospective cohort study of patients with ACHD in the Mayo ACHD Registry who had a verifiable residential address between January 1, 2004 and December 31, 2023. Clinical and SDOH indicators were extracted, including insurance type, language, rural–urban commuting area code, and a housing‐based socioeconomic index, an individual‐level measure of socioeconomic status derived from 4 objective housing characteristics and categorized into quartiles (Q1–Q4). Cox proportional‐hazards models were fitted to evaluate associations with mortality, incorporating CHD severity, arrhythmias, SDOH indicators, and other comorbidities. County of residence was included as a random effect, and model discrimination was assessed using the concordance statistic. Results Among 6134 patients with ACHD, the mean age was 38±16 years; 51% were male; 78.7% were White and 44.9% had rural residence. Independent predictors of mortality included cyanotic CHD (adjusted hazard ratio [aHR], 5.70 [95% CI, 2.90–11.23]), Fontan palliation (aHR, 4.98 [95% CI, 2.56–9.70]), ventricular tachycardia (aHR, 1.71 [95% CI, 1.16–2.52]), older age at first visit (aHR, 1.05 per year [95% CI, 1.04–1.05]), male sex (aHR, 1.19 [95% CI, 1.03–1.39]), public insurance (aHR, 1.60 [95% CI, 1.35–1.90]), rural residence (aHR, 1.25 [95%, CI 1.06–1.47]), and non‐English language (aHR 1.75 [95% CI 1.38–2.23]). The housing‐based socioeconomic index quartile was not associated with mortality. The final model achieved a concordance statistic of 0.77. Conclusions Mortality in patients with ACHD is strongly influenced by both clinical factors and SDOH, independent of socioeconomic status. Addressing barriers to care such as language, insurance, and geography is essential for improving ACHD survival particularly in those at increased mortality risk.
Identification of the Novel HLA ‐A*32:202 Allele by Next‐Generation Sequencing and Oxford Nanopore Sequencing
Siegel, Ruby J. , Ho, S., Hacke, Katrin, Ridgley, Rose M., Jaramillo, Andrés, Ho, Chak‐Sum , Jaramillo, Andrés , Hacke, Katrin , Ho, Sam , Hacke, Katrin , Jaramillo, Andres , Ho, Sam

Mayo Clinic

HLA | March 25, 2026 | Volume: 107 | Issue: 4 | Pages: No page available

10.1111/tan.70687 | PMID 41877497 Get It

ABSTRACT HLA‐A*32:202 differs from HLA‐A*32:01:01:01 by two nucleotide substitutions in exons 1 and 2.
Generative AI and large language model evaluation of kidney donation websites: Benchmarking health literacy, sentiment, and digital engagement to optimize donor recruitment
Bizer, Benjamin, Arriola‐Montenegro, Jose , Thongprayoon, Charat , Craici, Iasmina , Garcia Valencia, Oscar, Arriola-Montenegro, Jose, Thongprayoon, Charat , Miao, Jing , Craici, Iasmina M, Cheungpasitporn, Wisit , Valencia, Oscar A. Garcia , Miao, Jing , Cheungpasitporn, Wisit

Mayo Clinic

DIGITAL HEALTH | March 25, 2026 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/20552076261437915 | PMID 41907358 Get It

Background Kidney transplantation offers substantial clinical and economic benefits for patients with end-stage kidney disease (ESKD), yet organ shortages persist. Enhancing public awareness and health literacy regarding kidney donation is essential for effective donor recruitment. While online patient education materials are primary drivers of public perception, their readability, digital engagement, and accessibility remain underexplored barriers. Methods We analyzed the most prominent kidney donation websites identified through U.S.-based Google searches, including 11 primary organizations and 16 affiliated subdomains, for a total of 27 websites. Readability was benchmarked using Flesch-Kincaid, SMOG, and Gunning Fog indices. To assess qualitative metrics, we deployed a generative AI framework utilizing a Large Language Model (Claude) to conduct automated sentiment analysis and tone evaluation, validated by human review. We systematically mapped digital engagement features, including multimedia, interactive tools, and multilingual support, to determine content comprehensiveness. Results Websites consistently provided accurate information with a generally positive or neutral tone. Average readability exceeded recommended levels, with a combined mean grade of 12.3; 34% of websites were written at a college-level reading standard. Consensus across content was high. Multimedia elements were widely used, but engagement features were limited; only 30% of sites included extensive testimonials, and interactive tools were absent. AI-based analysis enabled standardized and reproducible evaluation, highlighting opportunities to improve accessibility, tone, and inclusivity. Conclusion Current U.S. kidney donation digital resources present a barrier to health equity due to excessive reading complexity and static engagement models. AI provides a scalable, reproducible framework to audit and optimize patient education materials. Future initiatives must leverage AI-guided content optimization to bridge the literacy gap, potentially increasing donor registration and access to transplantation.
Advancing radiation oncology care in Ukraine during the war: impact of international observerships on professional development and clinical practice
Lozko, Yuliia, Iakovenko, Viktor, Zelinskyi, Ruslan , Shepil, Zoia , Brovchuk, Serhii , Kowalchuk, Roman, Ford, Eric, Li, Ben, Strauss, Jonathan, Seuntjens, Jan, Breiktreutz, Dylan, Avery, Stephen, Viswanathan, Akila N., Aland, Trent, Koscharsky, Ross, Walsh, Anthony, Chen, Allen, Chang, Daniel T., Le, Quynh‐Thu , Kovalchuk, Nataliya , Le, Quynh-Thu , Beznosenko, Andriy , Suchowerska, Natalka , Iakovenko, Viktor , Strauss, Jonathan Blake , Das, Indra J. , Seuntjens, Jan P. , Wong, Rebecca K.S. , Breiktreutz, D., Avery, S.M., Viswanathan, Akila N. , Aland, Trent , Koscharsky, R.

Mayo Clinic

Frontiers in Oncology | March 25, 2026 | Volume: 16 | Issue: No issue available | Pages: No page available

10.3389/fonc.2026.1752691 | PMID 41959906 Get It

Objective This study evaluates the impact of international observerships organized by Help Ukraine Group (HUG) on professional development, knowledge transfer, and clinical practice improvement in radiation oncology in Ukraine. Methods A total of 50 observerships were facilitated for Ukrainian medical professionals at 14 institutions across the USA, Canada, Europe, and Australia from 2022 to 2024, including 31 radiation oncologists and medical physicists. A survey assessed their impact on oncology care, focusing on knowledge gained, lessons learned, and challenges in implementing new techniques. The primary outcome was the success score, defined as a composite score of implementing new procedures, initiating improvement projects, and knowledge dissemination efforts. Descriptive and comparative analyses examined satisfaction and success outcomes. Results A total of 43 respondents participated in the survey (response rate 86.0%). Twenty-eight of the responders were radiation oncology professionals (67.8% radiation oncologists, 32.1% medical physicists). The median observership duration for radiation oncology professionals was four weeks, with 96.4% also attending a professional conference. Overall satisfaction was high (mean 9.5 out of 10, median 10.0, IQR 9.0-10.0) while the success score was substantial (mean 6.1 out of 10, median 7.0, IQR 5.0-8.0). Time since certification influenced success, with ≥10 years’ experience associated with higher success scores (7.4 vs. 4.7, p=0.01). Importantly, 100% of respondents learned new procedures, 89.3% reported shifts in their clinical perspective, and 60.7% successfully implemented new techniques. Subsequent knowledge dissemination in Ukraine was substantial: 82.1% provided informal training, 60.7% delivered institutional or national presentations, 39.3% incorporated materials into lectures, and 10.7% engaged in all activities. Continued mentorship with host institutions was reported by 82.1%. Conclusions Amid the war, international observerships advanced clinical practice, education, and procedures in Ukraine, demonstrating the resilience of its medical community and providing a model that other LMICs/UMICs can follow.
Belt buckle ectropion: a distinct mechanism of lower eyelid malposition after Mohs reconstruction
Pasa, Gokce Cinel, Demer, Addison M. , Wagner, Lilly H.

Mayo Clinic

Frontiers in Ophthalmology | March 25, 2026 | Volume: 6 | Issue: No issue available | Pages: No page available

10.3389/fopht.2026.1804372 | PMID 41958923 Get It

Belt buckle ectropion is a newly recognized mechanism of lower eyelid malposition following Mohs reconstruction. Unlike cicatricial ectropion caused by vertical skin shortage, this variant results from horizontal flap tension acting on a lax tarsus. We retrospectively reviewed three patients who developed postoperative ectropion following subciliary Mohs reconstruction without lid margin involvement. Mechanism, management, and outcomes were analyzed. In all cases, the ectropion resulted from horizontal anterior lamellar tension producing anterior tarsal tilt, confirmed by a negative forced traction test. One case resolved spontaneously, and two required lateral tarsal strip procedures, both yielding successful anatomic and functional outcomes. Belt buckle ectropion represents a distinct post-reconstructive malposition mechanism, correctable with horizontal tarsal tightening rather than skin grafting. Recognition of this pattern may prevent misclassification as cicatricial ectropion and guide appropriate surgical management.
The American Society of Clinical Psychopharmacology (ASCP) task force on the deprescribing of psychotropic medications for mood disorders: Delphi expert consensus
Goldberg, Joseph F. , McIntyre, Roger S. , Mago, Rajnish, Jha, Manish K. , Berk, Michael , Kasper, Siegfried , Freeman, Marlene P. , GITLIN, MICHAEL J., Ostacher, Michael J. , Citrome, Leslie, Iosifescu, Dan V., Thase, Michael E., Young, Allan H. , Tohen, Mauricio, Nierenberg, Andrew A., Macaluso, Matt, Shelton, Richard C., Correll, Christoph U., Rosenblat, Joshua D., Gorwood, Philip, Khan, Arifulla, Kupka, Ralph, Cohen, Lawrence J., Mitchell, Philip B., Frye, Mark A., Sanacora, Gerard, Kane, John M., D, Goodman, Zohar, Joseph, Davis, Lori, Gupta, Swapnil , Steingard, Sandra , Zarate, Carlos A., Clayton, Anita H., Cohen, Lawrence J. , McIntyre, Roger S , Malhi, Gin S , Jha, Manish K , Berk, Michael , Kasper, Siegfried , Sajatovic, Martha , Ostacher, Michael J , Perlis, Roy H , Furukawa, Toshi A , Vieta, E , Young, Allan H , Aaronson, Scott T , Rubio, Jose M , Swartz, Holly A. , Malhi, Gin S. , Gitlin, Michael , Citrome, Leslie , Vieta, Eduard , Thase, Michael E. , Tohen, Mauricio , Nierenberg, Andrew A. , Shelton, Richard C. , Correll, Christoph Ulrich , Rosenblat, Joshua D. , Gorwood, Philip , Kupka, Ralph , Mitchell, Philip B , Frye, Mark A. , Sanacora, Gerard , Kane, John M., Zohar, Joseph , Davis, Lori L. , Gupta, Swapnil, Zarate, Carlos A. , Clayton, Anita H.

Mayo Clinic

The British Journal of Psychiatry | March 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-9

10.1192/bjp.2026.10580 | PMID 41877318 Get It

Summary The American Society of Clinical Psychopharmacology convened a 45-member international expert task force to identify circumstances supporting the deprescribing of core psychotropic medications for major depressive disorder (MDD) and bipolar disorders. Three Delphi survey rounds plus a selective literature review identified points of consensus (predefined as ≥75% agreement) about when antidepressant, antipsychotic, mood stabiliser and sedative-hypnotic deprescribing is warranted. Twenty out of 32 statements (63%) achieved consensus across seven thematic areas. In MDD, panellists favoured discontinuing antidepressants when mechanisms of action are duplicative, adequate trials produce ≤25% improvement or loss of prior efficacy cannot be regained through dose increases or augmentations. Indefinite antidepressant maintenance in MDD was favoured after three or more lifetime episodes. In bipolar disorder, antidepressant deprescribing was favoured in the setting of rapid cycling, mixed features or emerging mania/hypomania symptoms; and discouraged if prior antidepressant cessation led to relapse. In nonpsychotic mood disorders, panellists favoured deprescribing antipsychotics that caused significant weight gain or tardive dyskinesia over adding pharmacological antidotes. Deprescribing to achieve an eventual medication-free status was considered inappropriate, in bipolar type 1, but not necessarily bipolar type 2 disorder. Although individualised circumstances necessarily inform psychopharmacology management, clinical presentations that misalign with existing pharmacotherapies may signal the desirability of cautious deprescribing.